Atrial Fibrillation

📋 Key Information Summary

📋

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting approximately 380,000 Australians, with prevalence increasing sharply with age and expected to double by 2050.
Classification: Paroxysmal (self-terminating within 7 days), persistent (sustained >7 days or requiring cardioversion), long-standing persistent (>12 months), and permanent (accepted by patient and clinician).
Diagnosis requires a 12-lead ECG showing absence of distinct P waves, irregularly irregular RR intervals, and fibrillatory baseline. Ambulatory monitoring (Holter, event recorders, implantable loop recorders) captures paroxysmal episodes.
Stroke risk stratification uses CHA₂DS₂-VASc. Score ≥2 in men or ≥3 in women mandates oral anticoagulation (OAC). Score 1 in men warrants individualised consideration.
DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are first-line over warfarin for non-valvular AF, with superior safety profiles and no routine INR monitoring required.
Warfarin remains essential for mechanical heart valves and moderate-to-severe mitral stenosis (valvular AF). Target INR 2.0–3.0 for most indications.
Rate control is first-line strategy for most patients. Target resting heart rate <110 bpm (lenient) or <80 bpm (strict). First-line agents include beta-blockers and non-dihydropyridine calcium channel blockers.
Rhythm control is preferred in younger, symptomatic patients, first detected AF, AF secondary to treatable cause, or when rate control fails. Options include antiarrhythmic drugs, cardioversion, and catheter ablation.
Catheter ablation (pulmonary vein isolation) is superior to antiarrhythmic drugs for maintaining sinus rhythm and is recommended as first-line in selected symptomatic patients, including those with HFrEF.
CHA₂DS₂-VASc components: CHF (+1), Hypertension (+1), Age ≥75 (+2), Diabetes (+1), Stroke/TIA/TE (+2), Vascular disease (+1), Age 65–74 (+1), Sex category female (+1).
Aboriginal and Torres Strait Islander peoples have significantly higher AF prevalence, younger age of onset, higher stroke rates, and lower anticoagulant use — culturally safe, community-based approaches are essential.
All anticoagulated patients require regular review of adherence, bleeding risk (HAS-BLED), renal function, and drug interactions. Reassess at least annually or with any clinical change.

Introduction & Australian Epidemiology

Atrial fibrillation (AF) is characterised by disorganised electrical activity in the atria, resulting in an irregularly irregular ventricular response and loss of coordinated atrial contraction. It is the most common sustained cardiac arrhythmia worldwide and carries significant morbidity through stroke, heart failure, reduced quality of life, and increased mortality.

In Australia, an estimated 380,000 people live with AF, though the true burden is likely higher due to undiagnosed paroxysmal episodes. AF prevalence increases with age: it affects approximately 1% of those under 60 years but rises to 8–10% in those aged 80 years and older. The AIHW reports AF-related hospitalisations exceeded 90,000 admissions annually, making it a leading cardiovascular cause of hospital presentation.

AF carries a five-fold increase in stroke risk, and AF-related strokes tend to be more severe with higher mortality and disability. The total economic cost of AF in Australia is estimated at over $1.5 billion annually, including direct healthcare costs and lost productivity.

Risk factors for AF include advancing age, hypertension, obesity, obstructive sleep apnoea, valvular heart disease, heart failure, diabetes, excessive alcohol intake, and hyperthyroidism. Modifiable risk factors should be aggressively addressed as part of a holistic AF management strategy, consistent with the AF Better Care (ABC) pathway endorsed by international guidelines.

⚠️

Up to one-third of AF episodes are asymptomatic. Undiagnosed AF carries the same stroke risk as symptomatic AF. Active screening in high-risk populations (age ≥65, post-stroke, implantable devices) should be considered per NHFA/CSANZ guidelines.

Classification & Diagnosis

Classification of Atrial Fibrillation

AF is classified based on temporal pattern and duration. Accurate classification guides management decisions regarding rate vs rhythm control strategy and anticoagulation approach.

First Detected

First-Diagnosed AF

Newly identified AF regardless of duration or severity of symptoms. No prior known episode. May or may not be symptomatic.

Setting: GP / ED assessment

Paroxysmal

Paroxysmal AF

Self-terminating episodes, usually within 48 hours, almost always within 7 days. Recurrent pattern with spontaneous conversion to sinus rhythm.

Setting: Ambulatory / GP monitoring

Persistent

Persistent AF

AF sustained beyond 7 days, or lasting less than 7 days but requiring pharmacological or electrical cardioversion to terminate.

Setting: Cardiology / EP referral

Long-standing Persistent

Long-Standing Persistent AF

Continuous AF lasting >12 months when rhythm control strategy is adopted. Requires more aggressive intervention.

Setting: EP specialist management

Permanent

Permanent AF

AF accepted by patient and clinician. Rhythm control strategy abandoned. Both parties agree not to pursue further rhythm restoration.

Setting: Ongoing GP / specialist co-management

ECG Diagnosis

The hallmark 12-lead ECG findings of AF are:

Absent P waves — replaced by irregular, low-amplitude fibrillatory (f) waves, best seen in leads V1, II, III, and aVF
Irregularly irregular RR intervals — the most readily identifiable feature at the bedside
Narrow QRS complex (unless aberrant conduction or pre-existing bundle branch block)
Absence of an isoelectric baseline between QRS complexes
Variable ventricular rate — typically 100–160 bpm if untreated; may be slow (<60 bpm) suggesting concomitant AV node disease or rate-controlling medication effect

🚨

Differential diagnosis: Atrial flutter with variable block, multifocal atrial tachycardia (MAT), and frequent atrial ectopics can mimic AF. If the atrial rate is organised at ~300 bpm with sawtooth pattern, consider atrial flutter. If three or more distinct P-wave morphologies with isoelectric baseline, consider MAT.

Ambulatory Monitoring

Since paroxysmal AF is often asymptomatic and may not be captured on a standard ECG, ambulatory monitoring plays a critical role in diagnosis:

Modality	Duration	Indication	Australian Availability
24–48-hour Holter monitor	1–2 days	Symptoms occurring daily	Widely available (MBS Item 11706)
Extended Holter / 7-day patch	7–14 days	Intermittent symptoms (weekly)	Available in most cardiology practices
Event recorder (external)	Up to 30 days	Infrequent symptoms (monthly)	Available; MBS Item 11707
Smartwatch / consumer devices	Continuous	Screening; symptom correlation	Not MBS-funded; clinical validation advised
Implantable loop recorder (ILR)	Up to 3 years	Cryptogenic stroke workup; infrequent paroxysmal AF	Available; requires procedural facility (MBS Item 38280)

Population Screening

The National Heart Foundation of Australia (NHFA) and Cardiac Society of Australia and New Zealand (CSANZ) recommend opportunistic pulse palpation during routine clinical encounters for patients aged ≥65 years. An irregular pulse should prompt a 12-lead ECG for confirmation. Systematic screening with single-lead ECG or automated devices may be considered in high-risk populations, including post-stroke patients and those aged ≥75 with additional risk factors.

Smartwatch-based photoplethysmography (PPG) detection algorithms show high specificity but moderate sensitivity. Any positive result from a consumer device requires confirmatory ECG before initiating anticoagulation.

Stroke Risk & Anticoagulation

CHA₂DS₂-VASc Score

The CHA₂DS₂-VASc score is the recommended tool for stroke risk stratification in non-valvular AF. It builds upon the earlier CHADS₂ score with additional risk factors, improving identification of truly low-risk patients.

Risk Factor	Points
C — Congestive heart failure (or LVEF ≤40%)	+1
H — Hypertension	+1
A₂ — Age ≥75 years	+2
D — Diabetes mellitus	+1
S₂ — Stroke/TIA/thromboembolism history	+2
V — Vascular disease (MI, PAD, aortic plaque)	+1
A — Age 65–74 years	+1
Sc — Sex category (female)	+1

Anticoagulation Thresholds

🚨

Critical decision point: CHA₂DS₂-VASc ≥2 in men or ≥3 in women = anticoagulation recommended. Score of 1 in men = anticoagulation should be considered. Score of 0 in men or 1 in women = no anticoagulation needed (annual reassessment). Antiplatelet monotherapy (e.g. aspirin alone) is no longer recommended for stroke prevention in AF — it is less effective and carries comparable bleeding risk to DOACs.

Anticoagulant Selection

Direct oral anticoagulants (DOACs) are recommended as first-line over warfarin for non-valvular AF based on the pivotal RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials, and endorsed by NHFA/CSANZ, ESC, and AHA/ACC guidelines.

💊

Apixaban

Eliquis® · Factor Xa inhibitor · DOAC

Adult dose 5 mg PO BD

Dose reduction 2.5 mg PO BD if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥133 µmol/L

Renal adjustment Mild–moderate impairment: no adjustment. Severe (eGFR 15–29): 2.5 mg BD. eGFR <15: not recommended

Key advantage Lowest bleeding risk among DOACs (ARISTOTLE trial)

PBS status ✔ PBS General Benefit

💊

Rivaroxaban

Xarelto® · Factor Xa inhibitor · DOAC

Adult dose 20 mg PO daily with evening meal

Dose reduction 15 mg PO daily if eGFR 15–49 mL/min

Renal adjustment eGFR 15–49: 15 mg daily. eGFR <15: avoid

Key advantage Once-daily dosing; must be taken with food for optimal absorption

PBS status ✔ PBS General Benefit

💊

Dabigatran

Pradaxa® · Direct thrombin inhibitor · DOAC

Adult dose 150 mg PO BD

Dose reduction 110 mg PO BD if age ≥80, concomitant verapamil, or high bleeding risk

Renal adjustment eGFR 30–49: 150 mg BD (or 110 mg BD if bleeding risk). eGFR <30: avoid

Key advantage Specific reversal agent (idarucizumab / Praxbind®)

PBS status ✔ PBS General Benefit

💊

Warfarin

Coumadin® / Marevan® · Vitamin K antagonist

Adult dose Individualised; typically start 2–5 mg PO daily, adjust per INR

Target INR 2.0–3.0 (TTR goal >70%). INR 2.5–3.5 for mechanical mitral valve

Renal adjustment No renal dose adjustment required; monitor INR frequently in renal impairment

Indication Mechanical heart valves, moderate-severe mitral stenosis (valvular AF)

PBS status ✔ PBS General Benefit

⚠️

DOACs are contraindicated in mechanical heart valves and moderate-to-severe mitral stenosis. The RE-ALIGN trial was terminated early due to excess thromboembolic and bleeding events with dabigatran in mechanical valve patients. Warfarin remains the standard of care for valvular AF.

Bleeding Risk — HAS-BLED Score

The HAS-BLED score identifies modifiable bleeding risk factors and promotes their correction. It should not be used to withhold anticoagulation but rather to trigger regular clinical review and correction of reversible risk factors.

Letter	Risk Factor	Points
H	Hypertension (uncontrolled, SBP >160 mmHg)	+1
A	Abnormal renal or liver function (1 point each)	+1 or +2
S	Stroke history	+1
B	Bleeding history or predisposition	+1
L	Labile INR (TTR <60%, only if on warfarin)	+1
E	Elderly (>65 years)	+1
D	Drugs (antiplatelets, NSAIDs) or alcohol excess	+1 or +2

HAS-BLED ≥3: High bleeding risk — not a contraindication to anticoagulation, but mandates closer monitoring, correction of modifiable factors (control BP, discontinue concomitant antiplatelet/NSAID, address alcohol use), and regular clinical review.

Left Atrial Appendage Occlusion

For patients with AF who have genuine contraindications to long-term anticoagulation (e.g. life-threatening haemorrhage, recurrent major bleeding despite optimal therapy), left atrial appendage occlusion (LAAO) with devices such as the Watchman™ may be considered. This requires referral to a specialist centre with procedural expertise. It is available in select Australian tertiary centres and is funded through hospital-based programmes in some states.

Rate Control Strategies

Rate control is the recommended initial strategy for most patients with AF, as demonstrated by the AFFIRM, RACE, and AF-CHF trials which showed no mortality benefit of rhythm control over rate control. The target heart rate remains controversial, but the RACE II trial supports a lenient target (resting HR <110 bpm) as non-inferior to strict control (<80 bpm) for most patients. A stricter target may be considered if symptoms persist at lenient targets.

ℹ️

Achieving rate control does NOT replace anticoagulation. Anticoagulation decisions are based on CHA₂DS₂-VASc score, independent of whether rate or rhythm control is pursued.

First-Line Rate Control Agents

💊

Metoprolol

Betaloc® / Lopresor® · Cardioselective beta-blocker

Adult dose 25–50 mg PO BD-TDS (sustained release 50–200 mg daily)

Acute AF (IV) 2.5–5 mg IV over 2 min, repeat up to 15 mg total

Avoid in Decompensated HF, severe asthma, HR <50 bpm, 2nd/3rd degree AV block

PBS status ✔ PBS General Benefit

💊

Bisoprolol

Cardicor® · Cardioselective beta-blocker

Adult dose 2.5–10 mg PO daily

Renal adjustment Max 10 mg daily; caution in severe renal impairment

Advantage Well tolerated in stable HFrEF (CIBIS-II evidence)

PBS status ✔ PBS General Benefit

💊

Diltiazem

Dilzem® · Non-dihydropyridine calcium channel blocker

Adult dose 180–360 mg PO daily (SR formulation)

Acute AF (IV) 0.25 mg/kg IV over 2 min; may repeat 0.35 mg/kg after 15 min

Avoid in HFrEF (LVEF <40%) — negative inotropic effect

PBS status ✔ PBS General Benefit

💊

Digoxin

Lanoxin® · Cardiac glycoside

Adult dose 62.5–250 µg PO daily (loading: 500 µg PO stat, then 250 µg 6-hourly × 3 doses)

Therapeutic range 0.5–0.9 ng/mL (lower range associated with better outcomes)

Renal adjustment eGFR <30: 62.5 µg daily; narrow therapeutic index in renal impairment

Key caution Not first-line monotherapy; best as adjunct. Avoid in hypokalaemia. Increased mortality concern when serum level >1.0 ng/mL in some analyses

PBS status ✔ PBS General Benefit

Rate Control Quick Reference

AF + HFrEF (LVEF ≤40%)

Beta-blocker (bisoprolol, carvedilol, metoprolol) ± digoxin

Avoid diltiazem/verapamil (negative inotropy)

AF + preserved EF

Beta-blocker OR diltiazem/verapamil

Either class appropriate as first-line

AF + COPD/Reactive airways

Diltiazem or verapamil preferred

Avoid non-selective beta-blockers; cardioselective agents with caution

AF + Wolff-Parkinson-White

Procainamide or urgent ablation

AVOID beta-blockers, CCBs, digoxin, adenosine — risk of VF via accessory pathway

🚨

Never use beta-blockers, calcium channel blockers, digoxin, or adenosine in AF with pre-excitation (WPW). These agents slow AV nodal conduction and can precipitate ventricular fibrillation via the accessory pathway. Procainamide or synchronised DC cardioversion are appropriate in this setting.

AV Node Ablation + Permanent Pacing

When pharmacological rate control is inadequate or poorly tolerated despite optimal combination therapy, AV node ablation with permanent pacemaker implantation ("ablate and pace") is an effective last-resort strategy. This creates complete heart block with reliable ventricular rate control via pacing.

Requires permanent pacemaker — typically DDDR or VVIR mode
Results in pacemaker dependency — irreversible procedure
Consider CRT-pacing (CRT-P) if LVEF <35–50% to reduce RV pacing-induced dyssynchrony
Improves quality of life in 80–90% of appropriately selected patients
Anticoagulation still required — patient remains in AF

Rhythm Control Strategies

Rhythm control aims to restore and maintain sinus rhythm. While earlier trials (AFFIRM, RACE) showed no mortality advantage over rate control, the EAST-AFNET 4 trial (2020) demonstrated that early rhythm control within 12 months of AF diagnosis significantly reduced cardiovascular outcomes (composite of stroke, HF, acute coronary syndrome, cardiovascular death), particularly in patients with low AF burden and fewer comorbidities.

✅

EAST-AFNET 4 changed practice: Early rhythm control should be considered in recently diagnosed AF (<12 months) with cardiovascular risk factors, especially if symptomatic. This does not negate the role of rate control in asymptomatic or older patients with established AF.

When to Choose Rhythm Control

Symptomatic AF despite adequate rate control
First-detected or recently diagnosed AF (<12 months) with CV risk factors (EAST-AFNET 4)
Younger patients where AF progression is a concern
AF precipitated by a reversible cause (e.g. hyperthyroidism, post-operative, alcohol)
Patient preference after shared decision-making
Tachycardia-mediated cardiomyopathy despite rate control
Intolerance to rate-controlling agents

Antiarrhythmic Drug Selection

Antiarrhythmic drugs for rhythm control in AF are classified per the Vaughan-Williams system. The choice depends on underlying structural heart disease, LVEF, and comorbidities.

💊

Flecainide

Tambocor® · Class Ic antiarrhythmic

Adult dose 50–200 mg PO BD

Pill-in-the-pocket 200–300 mg PO stat for infrequent paroxysmal AF (trial under observation first)

Contraindications Structural heart disease, CAD, HFrEF, significant LVH — increased pro-arrhythmic risk

Key monitoring QRS duration; avoid in combination with amiodarone

PBS status ✔ PBS General Benefit

💊

Amiodarone

Aratac® · Class III multi-class antiarrhythmic

Adult dose Loading: 200 mg PO TDS × 1 week → 200 mg BD × 1 week → maintenance 200 mg daily (or alternate day)

IV loading 5 mg/kg over 1 hour, then 900–1200 mg over 24 hours via CIVI

Key advantage Safe in structural heart disease and HFrEF; most effective antiarrhythmic for AF

Monitoring TFTs (6-monthly), LFTs, CXR (annual), ophthalmology review; risk of thyroid, hepatic, pulmonary toxicity

PBS status ✔ PBS General Benefit

💊

Sotalol

Sotacor® · Class III / non-selective beta-blocker

Adult dose 80–160 mg PO BD

Renal adjustment eGFR 30–60: 80 mg daily. eGFR 10–30: 80 mg alternate day. eGFR <10: avoid

Caution QTc prolongation risk; avoid if QTc >500 ms or significant hypokalaemia

PBS status ✔ PBS General Benefit

💊

Dronedarone

Multaq® · Class III multi-class antiarrhythmic

Adult dose 400 mg PO BD

Contraindications HFrEF (NYHA III–IV), permanent AF, severe hepatic impairment — PALLAS trial showed increased mortality in these groups

Advantage Lower toxicity than amiodarone; no thyroid/retinal monitoring needed

PBS status 🔶 PBS Authority Required

Antiarrhythmic Drug Selection by Heart Disease

Clinical Scenario	First-Line	Second-Line	Avoid
No structural heart disease	Flecainide or propafenone	Sotalol, dronedarone, or catheter ablation	—
Coronary artery disease	Sotalol or dronedarone	Amiodarone, catheter ablation	Flecainide, propafenone
HFrEF (LVEF ≤40%)	Amiodarone or catheter ablation	Dronedarone (mild HF only)	Flecainide, propafenone, sotalol
Hypertrophic cardiomyopathy	Amiodarone	Dronedarone, catheter ablation	Flecainide, propafenone

Pharmacological Cardioversion

Pharmacological cardioversion is most effective within 7 days of AF onset. Options include:

Flecainide PO 200–300 mg stat (if no structural heart disease) — conversion rate ~50–70% within 3–6 hours
Amiodarone IV — slower onset but safe in structural heart disease; may convert over 24 hours
Vernakalant IV (Kynapid®) — approved in Australia for rapid conversion of recent-onset AF (<7 days); MBS access limited to hospital use
Flecainide + oral beta-blocker combo — "pill-in-the-pocket" approach for patients with infrequent, well-tolerated paroxysmal AF

⚠️

Cardioversion and thromboembolism: If AF duration is ≥24 hours or unknown, anticoagulation must be therapeutic for ≥3 weeks before elective cardioversion. Alternatively, TOE-guided approach (to exclude LA/LAA thrombus) with early cardioversion can be performed with therapeutic anticoagulation. If AF ≥48 hours, DO NOT cardiovert without anticoagulation strategy.

Electrical Cardioversion

Synchronised DC cardioversion is performed under procedural sedation (propofol or midazolam + fentanyl) with continuous monitoring. Biphasic defibrillators are standard, with initial energy of 120–200 J biphasic. Success rates exceed 90% for recent-onset AF. Paddles should be placed in anterolateral or anteroposterior positions. All patients require the same anticoagulation strategy as for pharmacological cardioversion.

Catheter Ablation

Pulmonary Vein Isolation (PVI)

Catheter ablation for AF is centred on pulmonary vein isolation (PVI), which electrically isolates the pulmonary veins from the left atrium to eliminate the triggers and substrate for AF. This is typically achieved using either radiofrequency (RF) ablation with point-by-point lesion sets or cryoballoon ablation which achieves single-shot PVI. Pulsed field ablation (PFA) is an emerging technology with tissue selectivity, reducing collateral damage to oesophagus and phrenic nerve.

Indications for Catheter Ablation

✅

Class I indication (NHFA/CSANZ 2024, ESC 2024): Catheter ablation is recommended as first-line therapy for symptomatic paroxysmal AF in preference to antiarrhythmic drugs, particularly in younger patients with few comorbidities. It is also recommended in symptomatic AF refractory to antiarrhythmic drugs regardless of AF type.

Paroxysmal AF: Recommended as first-line or after failure of one antiarrhythmic drug. Single-procedure success rate 70–80% at 1 year
Persistent AF: Recommended after failure of antiarrhythmic drugs. May require substrate modification beyond PVI. Success rate 50–70% at 1 year
Long-standing persistent AF: Considered in selected symptomatic patients. Lower success rate (40–60%); may require multiple procedures
AF with HFrEF: CASTLE-AF trial demonstrated mortality and HF hospitalisation benefit of ablation vs medical therapy. Recommended when AF is contributing to ventricular dysfunction
Patient preference: Shared decision-making; some patients prefer ablation over lifelong antiarrhythmic drug therapy

Procedural Success Rates

AF Type	Single Procedure Success (1 year)	Multiple Procedures Success (1 year)	5-Year Freedom from AF
Paroxysmal	70–80%	80–90%	50–70%
Persistent	50–70%	65–80%	40–60%
Long-standing persistent	40–60%	55–70%	30–50%

Complications

Catheter ablation for AF carries a recognised complication profile. Overall major complication rate is 2–4% at experienced centres:

Cardiac tamponade (1–2%) — most significant acute emergency; requires pericardiocentesis
Pulmonary vein stenosis (<1%) — reduced with modern wide-antral isolation techniques
Atrio-oesophageal fistula (0.01–0.25%) — rare but highly lethal; presents days to weeks post-procedure with fever, neurological symptoms, mediastinitis. High index of suspicion required
Phrenic nerve injury (0.5–2%) — more common with cryoballoon; usually transient
Stroke/TIA (0.5–1%) — minimised with anticoagulation and heparinisation during procedure
Vascular access complications (2–4%) — haematoma, pseudoaneurysm, AV fistula
Death (<0.1%) — extremely rare

Repeat Procedures

A significant proportion of patients require repeat ablation procedures. Pulmonary vein reconnection is the most common mechanism of AF recurrence. For paroxysmal AF, a second procedure is needed in 20–30% of patients. For persistent AF, 30–50% may require a second procedure. A third procedure is uncommon and should prompt re-evaluation of the rhythm control strategy. A blanking period of 3 months post-ablation should be observed before assessing treatment failure, as early recurrences (up to 50%) may resolve with healing and antiarrhythmic drug therapy during this period.

Australian Access

Catheter ablation for AF is available at major metropolitan centres across all Australian states and territories. Waiting times in the public system can be 3–12 months depending on the centre. Private health insurance typically covers the procedure with minimal out-of-pocket costs at participating hospitals. Regional and remote patients may need to travel for the procedure, with post-operative follow-up coordinated with local cardiologists. MBS Item 38258 covers catheter ablation of arrhythmogenic substrate.

Special Populations

🫀

AF with HFrEF

Management approach

AF and HFrEF frequently coexist and worsen each other (tachycardia-mediated cardiomyopathy). The CASTLE-AF trial demonstrated that catheter ablation reduced composite endpoint of death or HF hospitalisation by 38% compared to medical therapy in patients with AF and HFrEF (LVEF ≤35%).

Rate control

Beta-blockers (bisoprolol, carvedilol, metoprolol succinate) are first-line. Diltiazem/verapamil are contraindicated. Digoxin may be added as adjunct. Target HR <110 bpm.

Rhythm control

Amiodarone is the safest antiarrhythmic. Dronedarone is contraindicated in NYHA III–IV (PALLAS trial). Flecainide/propafenone are contraindicated. Catheter ablation should be strongly considered.

Anticoagulation

DOACs are preferred (apixaban has best evidence in HFrEF). CHA₂DS₂-VASc applies. Heart failure alone scores +1.

🫀

Valvular AF

Definition

"Valvular AF" specifically refers to AF with mechanical heart valves or moderate-to-severe mitral stenosis (typically rheumatic). This definition has been clarified in recent guidelines to exclude patients with bioprosthetic valves or those who have undergone valve repair.

Anticoagulation

Warfarin is mandatory. DOACs are contraindicated in mechanical valves and moderate-severe mitral stenosis. Target INR 2.0–3.0 for most mechanical aortic valves; INR 2.5–3.5 for mechanical mitral valves. DOACs may be considered for bioprosthetic valves ≥3 months post-implant, or for AF with mild mitral stenosis.

Rate/rhythm control

Standard agents apply, with attention to haemodynamic impact of the underlying valve lesion. Surgical maze procedure may be considered at time of valve surgery.

🏥

Post-Operative AF

Incidence

Post-operative AF (POAF) occurs in 20–50% of cardiac surgery patients and 1–5% of non-cardiac thoracic surgery. Peak incidence is post-operative days 2–4. Most episodes self-terminate within 6 weeks.

Prevention

Perioperative beta-blockers (continue if already on therapy). Amiodarone prophylaxis in high-risk cardiac surgery patients. Colchicine may reduce POAF post-cardiac surgery. Avoid fluid overload.

Treatment

Rate control with beta-blockers as first-line. Amiodarone IV if haemodynamically significant. Cardioversion for haemodynamic instability. Anticoagulation if AF persists >48 hours or CHA₂DS₂-VASc ≥2. May be discontinued at 6-week follow-up if sinus rhythm restored and no other indication.

🏃

Athlete's Heart & AF

Epidemiology

Endurance athletes have a 2–5× increased risk of AF, likely mediated by vagal tone, atrial remodelling, atrial fibrosis, and inflammation. Lone AF in athletes is often vagally mediated (nocturnal, during rest/cool-down).

Initial management

Address modifiable factors (alcohol, stimulant use, overtraining). Catheter ablation is preferred over antiarrhythmic drugs in competitive athletes, as most antiarrhythmic drugs are either banned (flecainide under some conditions) or impair exercise capacity. Beta-blockers are prohibited in some competition contexts.

Anticoagulation

Standard CHA₂DS₂-VASc risk assessment applies. Young athletes with lone AF and CHA₂DS₂-VASc of 0 may not require anticoagulation. Trauma risk in contact sports must be considered if anticoagulated. Shared decision-making essential.

🫘

Renal Impairment

DOAC dosing

Apixaban: preferred in CKD 4 (eGFR 15–29) at reduced dose 2.5 mg BD. Rivaroxaban: 15 mg daily if eGFR 15–49. Dabigatran: avoid if eGFR <30. All DOACs: avoid if eGFR <15 or on dialysis (warfarin may be required). Regular eGFR monitoring every 6–12 months.

Rate control

Digoxin requires dose reduction and therapeutic drug monitoring. Beta-blockers: dose adjust for severe impairment. Diltiazem: generally safe.

👶

Pregnancy

Incidence

AF in pregnancy is uncommon (incidence ~1–2 per 1000 pregnancies) but can occur in women with structural heart disease, thyrotoxicosis, or WPW syndrome.

Rate control

Metoprolol or atenolol are preferred beta-blockers. Verapamil is an alternative. Avoid diltiazem in pregnancy. Digoxin is considered safe but monitor levels.

Anticoagulation

DOACs are contraindicated in pregnancy. Warfarin is contraindicated in the first trimester (teratogenicity) but may be used in second/third trimesters. Low-molecular-weight heparin (LMWH) is the standard anticoagulant in pregnancy — enoxaparin 1 mg/kg SC BD (monitor anti-Xa levels). Unfractionated heparin IV for acute cardioversion.

Cardioversion

Synchronised DC cardioversion is safe in pregnancy at any gestational age. Fetal monitoring should be performed during the procedure. Amiodarone should be avoided (fetal thyroid effects).

Investigations

A structured diagnostic workup is essential for every patient presenting with AF. Investigations should identify reversible causes, assess cardiac structure and function, quantify stroke and bleeding risk, and guide management strategy.

Essential

12-Lead ECG

Confirms AF diagnosis; identifies ischaemic changes, LVH, pre-excitation (WPW), QTc prolongation (for antiarrhythmic safety), and alternative arrhythmias.

Essential

Thyroid Function Tests (TFTs)

TSH, free T3, free T4. Hyperthyroidism is a reversible cause of AF. Hypothyroidism may also predispose. Amiodarone-induced thyroid dysfunction requires baseline TFTs.

Essential

Renal Function (eGFR, Creatinine)

Determines DOAC dosing and safety. Baseline before initiating anticoagulation; repeat at least annually or more frequently in CKD.

Essential

Full Blood Examination (FBE)

Identifies anaemia (predisposes to AF, affects anticoagulation decision-making), thrombocytopaenia (bleeding risk), and infection/inflammation.

Essential

Liver Function Tests (LFTs)

Baseline before anticoagulation. Hepatic impairment affects DOAC clearance (apixaban/edoxaban less affected). For amiodarone monitoring.

Essential

Electrolytes (including Magnesium)

Hypokalaemia and hypomagnesaemia can trigger AF and increase pro-arrhythmic risk with sotalol/flecainide. Correct prior to antiarrhythmic therapy.

Available

Transthoracic Echocardiography (TTE)

Assesses LVEF, valvular disease (mitral stenosis), LA size, LV hypertrophy. Essential for guiding rate vs rhythm control strategy and anticoagulation indication. MBS Item 55118.

Available

Transoesophageal Echocardiography (TOE)

Excludes LA/LAA thrombus prior to cardioversion (TOE-guided strategy). Alternative to 3 weeks of therapeutic anticoagulation pre-cardioversion. MBS Item 55125.

Available

Ambulatory ECG Monitoring (Holter / Event Recorder)

For paroxysmal AF detection and symptom correlation. 24–48 hour Holter (MBS Item 11706), extended monitoring (MBS Item 11707).

Available

Chest X-Ray

Assesses for pulmonary pathology, cardiac silhouette, and pulmonary congestion. Helpful in acute AF to exclude precipitants.

Specialist

CT Cardiac / Cardiac MRI

Cardiac MRI for assessment of atrial fibrosis (late gadolinium enhancement) pre-ablation planning. CT for pulmonary vein anatomy and LA mapping. Available at tertiary centres.

Specialist

Electrophysiology Study (EPS)

For evaluation of accessory pathways in WPW and mapping prior to catheter ablation. Performed at specialist electrophysiology centres.

Monitoring

Anticoagulation Monitoring

Baseline

eGFR, LFTs, FBE, coagulation screen. Confirm CHA₂DS₂-VASc and HAS-BLED scores. Document indication and chosen agent.

2 weeks

Early review for adherence, side effects (bleeding, GI symptoms for dabigatran). Recheck renal function if risk of AKI.

3 months

Formal review: ongoing adherence, bleeding assessment, renal function. If on warfarin — review TTR (target >70%), consider switching to DOAC if TTR consistently <65%.

6-monthly

eGFR, LFTs (for DOACs and amiodarone). TFTs if on amiodarone. Bleeding risk reassessment (HAS-BLED). Ongoing adherence counselling.

Annually

Comprehensive review: CHA₂DS₂-VASc reassessment, HAS-BLED reassessment, renal function, consideration of ongoing rhythm control strategy, patient education reinforcement.

Warfarin-Specific Monitoring

INR target: 2.0–3.0 (2.5–3.5 for mechanical mitral valve)
INR frequency: weekly until stable (3 consecutive INRs in range), then every 2–4 weeks
Time in therapeutic range (TTR): aim >70% (Rosendaal method). If TTR consistently <65%, consider switching to DOAC
Patient self-monitoring (home INR testing) is supported and improves TTR in motivated patients
Significant drug interactions: antibiotics (metronidazole, fluconazole, macrolides), amiodarone (reduce warfarin dose by 30–50%), anticonvulsants, St John's wort

Antiarrhythmic Drug Monitoring

Drug	Monitoring Required	Frequency
Amiodarone	TFTs, LFTs, CXR, ophthalmology review	TFTs/LFTs: 6-monthly. CXR: annual. Ophthalmology: annual
Sotalol	ECG (QTc), renal function, electrolytes	ECG: after initiation, dose change, and at steady state. Renal: 6-monthly
Flecainide	ECG (QRS duration), drug level if renal impairment	ECG: after initiation and annually
Dronedarone	ECG (QTc), LFTs, renal function	LFTs: baseline, then periodically. ECG: after initiation

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of atrial fibrillation and its complications. Data from the AIHW and the Busselton Health Study demonstrate that Indigenous Australians develop AF at a younger age, have higher rates of comorbid conditions (rheumatic heart disease, diabetes, chronic kidney disease, obesity), and experience significantly higher rates of AF-related stroke and cardiovascular mortality compared to non-Indigenous Australians.

Despite the higher disease burden, studies consistently demonstrate lower rates of anticoagulant prescription in Indigenous AF patients. This "treatment gap" reflects systemic barriers including access to specialist care, medication affordability (particularly in remote communities), health literacy, cultural safety of health services, and the complexity of medication regimens.

⚠️

Critical disparity: Aboriginal and Torres Strait Islander peoples are hospitalised for AF at 1.6 times the rate of non-Indigenous Australians, yet are significantly less likely to be prescribed anticoagulation. Closing this treatment gap is a national priority per the NHFA and AIHW cardiovascular health strategies.

Rheumatic Heart Disease (RHD)

RHD prevalence in remote NT communities exceeds 30 per 1000 (vs <1 per 1000 nationally). RHD-related mitral stenosis is a major cause of valvular AF in Indigenous Australians, requiring warfarin (not DOACs). The RHD Endgame Strategy (2020–2031) prioritises secondary prophylaxis and anticoagulation access.

Remote & Rural Access

Many Indigenous Australians live in remote communities where specialist cardiology and EP services are unavailable. Telehealth (MBS Items 99200–99215) supports remote specialist consultation. Point-of-care INR testing (CoaguChek®) enables warfarin monitoring in communities without pathology services. Medication supply through Remote Area Aboriginal Health Services (RAAHS) and Section 100 arrangements.

Medication Access & PBS

DOACs are PBS-listed as General Benefits and available through the PBS without Authority requirement, improving accessibility. Warfarin is similarly PBS-listed but requires INR monitoring infrastructure. Section 100 (S100) Highly Specialised Drugs Program supports access to specific cardiac medications in remote Aboriginal Medical Services. Close liaison with community pharmacists and Aboriginal health workers is essential for medication adherence.

Cultural Safety

Management should be delivered through Aboriginal Community Controlled Health Organisations (ACCHOs) where possible. Aboriginal and Torres Strait Islander health workers and practitioners are vital for health education, medication support, and building trust. Consultation should incorporate yarning-based approaches and be sensitive to family and community decision-making structures. Gender considerations may affect consultation preferences.

Screening & Early Detection

Opportunistic pulse palpation at every health encounter is particularly important given younger AF onset. Smartwatch/photoplethysmography devices may have limited uptake in remote settings. Single-lead ECG devices (e.g. KardiaMobile®) have been successfully deployed in some ACCHO settings for community-based AF screening programs.

Comorbidity Burden

Indigenous Australians with AF have higher rates of concurrent diabetes (up to 4× non-Indigenous), CKD (affecting DOAC dosing), hypertension, obesity, and rheumatic heart disease. Holistic, integrated chronic disease management through primary healthcare is essential, aligning with the National Aboriginal and Torres Strait Islander Health Plan 2021–2031.

AF Better Care (ABC) Pathway — Holistic Management

The AF Better Care (ABC) pathway, endorsed by the ESC and NHFA/CSANZ, provides a structured approach to integrated AF management. It has been shown to reduce stroke, major bleeding, cardiovascular mortality, and all-cause mortality when consistently applied.

A

Anticoagulation / Avoid Stroke

Assess CHA₂DS₂-VASc and initiate appropriate OAC (DOAC preferred for non-valvular AF). Address HAS-BLED modifiable factors. Ensure adherence support.

B

Better Symptom Management

Patient-reported symptoms guide rate vs rhythm control strategy. Use validated symptom scores (EHRA score). Address patient preferences through shared decision-making.

C

Cardiovascular & Comorbidity Optimisation

Manage hypertension (target <130/80 mmHg), diabetes, obesity (weight management), OSA (CPAP), heart failure, alcohol reduction, and physical activity. These interventions reduce AF burden and improve outcomes.

📚 References

1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.
2. Brieger D, Amerena J, Attia J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018;27(10):1209-1266.
3. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305-1316. (EAST-AFNET 4 trial)
4. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-427. (CASTLE-AF trial)
5. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-1373. (RACE II trial)
6. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. (ARISTOTLE trial)
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. (RE-LY trial)
8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. (ROCKET-AF trial)
9. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. (ENGAGE AF-TIMI 48 trial)
10. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833. (AFFIRM trial)
11. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-272.
12. Australian Institute of Health and Welfare (AIHW). Atrial fibrillation in Australia. Cat. no. CVD 87. Canberra: AIHW; 2022.
13. National Heart Foundation of Australia. Guidelines for the management of absolute cardiovascular disease risk. Melbourne: NHF; 2012 (updated 2023).
14. Australian Institute of Health and Welfare (AIHW). Cardiovascular disease in Aboriginal and Torres Strait Islander people. Cat. no. CDK 10. Canberra: AIHW; 2023.
15. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-e444.
16. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-132.
17. Crijns HJ, Weijs B, Fairley AM, et al. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. Int J Cardiol. 2014;172(3):588-594.